Topic: P015 ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer’s disease

 Date/Time: Monday, November 16, 2:00 p.m. – Tuesday, November 17, 5:30 p.m. EST